Eli Lilly Announces $2.5 Billion Investment in New High-Tech Injectable Manufacturing Facility in Alzey, Germany

BerlinNovember 20, 2023PR Newswire -- Eli Lilly and Company announced plans to invest $2.5 billion (€2.3 billion) in building a new high-tech production facility in Alzey, Rhineland-Palatinate. The company also plans to invest up to $100 million in the startup ecosystem of Germany's life sciences and biotechnology industries.

Alzey's new production base is scheduled to commence operations in 2027, employing up to 1,000 highly skilled professionals. The facility will utilize state-of-the-art technologies such as automated systems and high-speed production lines to manufacture pharmaceuticals, contributing to an improved quality of life. Workers from Germany's pharmaceutical industry, with their extensive experience, will play a crucial role in strengthening the supply of insulin-based medications by Eli Lilly and Company. Construction of the production base is set to begin in 2024, during which up to 1,900 new jobs will be created.Germany Trade & Invest(GTAI) provided support for Eli Lilly and Company in finding a factory site.

Managing Director of Germany's Federal Foreign Trade and Investment AgencyRobert Hermann said:"This investment once again demonstrates the attractiveness of Germany as an investment location. It also strengthens Germany's position as a pharmaceutical hub and enhances the independence of the industry's supply chain. From our perspective, it doesn't get any better than this: an innovative multinational company investing in Germany, creating high-quality jobs, with both Germany and Europe benefiting from the products produced here."

Germany Trade & Invest (GTAI) is the economic development agency of the Federal Republic of Germany. The organization provides consulting and support to foreign companies entering the German market and assists businesses established in Germany in entering foreign markets.

Contact Person:Cao Yi,
Phone: 0049 15118052385
Email:yi.cao@gtai.eu